Exciting Developments in HPV-Driven Cancer Research
Kronos Bio, Inc. has announced groundbreaking findings in the area of treating HPV-driven cancers, which continue to impact a significant number of patients globally. They are focused on utilizing the p300 KAT inhibitor, KB-9558, to target specific oncogenic components of human papillomavirus (HPV). This initiative is particularly important as HPV remains a leading cause of certain cancers, including cervical and head and neck cancers.
Key Findings from Preclinical Research
Recent studies demonstrated that the p300 KAT inhibitor KB-9558 effectively inhibits the oncogenic HPV-16 E6 and E7 proteins. This inhibition leads to a reactivation of the tumor suppressor protein p53, which plays a crucial role in controlling cell growth and preventing cancer formation. By downregulating these viral oncoproteins, Kronos Bio aims to combat the progression of tumors associated with HPV.
Innovative Therapeutics for a Persistent Problem
Despite advancements in medical science, HPV still accounts for many new cancer diagnoses every year. Charles Lin, Ph.D., the Chief Scientific Officer at Kronos Bio, emphasized the importance of developing targeted therapies. He mentioned, "HPV-driven cancers are often fueled by viral oncoproteins that provide unique therapeutic targets, and our approach aims at providing patients with these innovative treatments."
Upcoming Symposium Presentation
Kronos Bio will present these exciting findings at the esteemed EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster presentation is scheduled for a specific time during the event, where the research will be further detailed. This event is a platform for Kronos Bio to share their advances and gather valuable feedback from the global research community.
Material Highlights from the Upcoming Presentation
Details of the presentation include:
Title: Oncogenic human papillomavirus hijacks p300 to drive viral transcription, creating a therapeutic vulnerability that can be exploited with selective p300/CBP catalytic inhibitors
Presenter: Marek Kobylarz, Ph.D., Senior Scientist
Poster Session: Epigenetic modulators (HDAC Bromodomain modulators, EZH2)
Date and Time: Thursday, October 24, 2024, from 9:00 a.m. to 5:30 p.m. CEST
About Kronos Bio and Their Mission
Kronos Bio prides itself on its deep commitment to unraveling the complexities of transcription regulation, which often goes awry in various diseases. Their proprietary technology focuses on identifying small molecule therapeutics aimed at druggable targets within these regulatory networks. Currently, their portfolio includes several promising candidates for various indications, preparing them to address critical unmet needs in the field of oncology.
Focus on Drug Development
KB-9558 stands out as a significant preclinical candidate aimed at treating HPV-driven tumors, while Kronos Bio's other candidates also aim to tackle multiple myeloma and autoimmune diseases. Their strategic focus on deregulated transcription represents a forward-looking approach in the biotechnology landscape.
Contacting Kronos Bio for More Information
For investors or media inquiries, Kronos Bio provides direct contact information:
Investors:
Margaux Bennett
Vice President, Corporate Development and Investor Relations
Phone: 650-781-5026
Email: mbennett@kronosbio.com
Media:
Kelli Perkins
Email: kelli@redhousecomms.com
Frequently Asked Questions
What is the main focus of Kronos Bio's research?
Kronos Bio focuses on developing small molecule therapeutics targeting deregulated transcription involved in cancer and autoimmune diseases.
What is KB-9558?
KB-9558 is a p300 KAT inhibitor being developed to target HPV-driven tumors by inhibiting oncogenic proteins.
When will Kronos Bio present their findings?
Kronos Bio will present their findings on October 24, 2024, at the EORTC-NCI-AACR Symposium.
Why are viral oncoproteins significant in cancer therapy?
Viral oncoproteins represent unique therapeutic targets because they are present only in tumor cells, making them ideal for targeted therapy.
How can I learn more about Kronos Bio?
Visit Kronos Bio's official website or follow them on LinkedIn for the latest updates and information.
